Tonix Pharmaceuticals Ownership
| TNXP Stock | USD 0.19 0.01 5.00% |
Shares in Circulation | First Issued 2008-03-31 | Previous Quarter 4.1 M | Current Value 62.1 M | Avarage Shares Outstanding 3.1 M | Quarterly Volatility 9.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tonix |
Tonix Stock Ownership Analysis
The company has price-to-book ratio of 0.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tonix Pharmaceuticals recorded a loss per share of 80.39. The entity last dividend was issued on the 1st of November 2019. The firm had 1:32 split on the 10th of June 2024. Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Tonix Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people. To find out more about Tonix Pharmaceuticals Holding contact the company at 862 799 8599 or learn more at https://www.tonixpharma.com.Besides selling stocks to institutional investors, Tonix Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tonix Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tonix Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tonix Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Tonix Pharmaceuticals Holding are currently held by insiders. Unlike Tonix Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tonix Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tonix Pharmaceuticals' insider trades
Tonix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tonix Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tonix Pharmaceuticals Holding backward and forwards among themselves. Tonix Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tonix Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 50.0 | Bank Of America Corp | 2024-06-30 | 28.0 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 10.0 | Jpmorgan Chase & Co | 2024-06-30 | 9.0 | Hanson Mcclain Inc | 2024-09-30 | 7.0 | Guaranty Trust Company Of Missouri | 2024-09-30 | 7.0 | Planning Capital Management Corp | 2024-09-30 | 7.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Global Retirement Partners, Llc. | 2024-09-30 | 2.0 | Geode Capital Management, Llc | 2024-09-30 | 116 K | Wedbush Morgan Securities Inc | 2024-09-30 | 40.5 K |
Tonix Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tonix Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tonix Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tonix Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bagger Richard H over six months ago Acquisition by Bagger Richard H of 104621 shares of Tonix Pharmaceuticals at 0.1745 subject to Rule 16b-3 | ||
Goodman Daniel Wintner over six months ago Acquisition by Goodman Daniel Wintner of 270882 shares of Tonix Pharmaceuticals at 1.03 subject to Rule 16b-3 | ||
Bradley Saenger over six months ago Acquisition by Bradley Saenger of 282000 shares of Tonix Pharmaceuticals at 0.368 subject to Rule 16b-3 | ||
Jessica Morris over six months ago Acquisition by Jessica Morris of 317000 shares of Tonix Pharmaceuticals at 0.46 subject to Rule 16b-3 | ||
Gregory Sullivan over six months ago Acquisition by Gregory Sullivan of 1250000 shares of Tonix Pharmaceuticals subject to Rule 16b-3 | ||
Stillwell Richard Newcomb over a year ago Acquisition by Stillwell Richard Newcomb of 60000 shares of Tonix Pharmaceuticals subject to Rule 16b-3 | ||
Bradley Saenger over a year ago Acquisition by Bradley Saenger of 200000 shares of Tonix Pharmaceuticals subject to Rule 16b-3 |
Tonix Pharmaceuticals Outstanding Bonds
Tonix Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tonix Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tonix bonds can be classified according to their maturity, which is the date when Tonix Pharmaceuticals Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Pair Trading with Tonix Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Tonix Stock
The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.
The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.